Molecular pathway appears crucial in development of pulmonar...( A study led by Massachusetts General...),Health
Navigation Links
Molecular pathway appears crucial in development of pulmonary fibrosis
Date:12/12/2007
A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment. The investigators found that a specific molecular pathway appears responsible for key aspects of the scarring of lung tissue that characterizes IPF, the cause of which is currently unknown. The results will appear in the January issue of Nature Medicine and have received early online release.
Identifying the key role of this pathway in the development of fibrosis gives us an exciting new target for devising treatments, says Andrew Tager, MD, of the MGH Pulmonary and Critical Care Unit, who led the study. An agent that blocks this pathway is already being developed as a potential cancer treatment, and were hoping to be able to test it in our animal model of IPF to determine whether it might be a candidate for trials in patients.
About 50,000 new cases of IPF are diagnosed in the U.S. each year, primarily in people aged 50 to 75. While some patients may survive for extended periods, in others the diseases progresses rapidly, leading to death in an average of 3 to 5 years. Theories about the cause of IPF previously focused on chronic inflammation of the lungs, but recent evidence has suggested that an abnormal healing response to some sort of lung injury may be responsible.
The primary characteristic of IPF is scarring (fibrosis) of the lung surface, rendering it unable to transmit oxygen into the bloodstream. In any part of the body, scarring occurs when cells called fibroblasts, an important part of normal wound healing, make collagen to reinforce the healing matrix that forms over damaged tissue. Normally scarring is limited, but if too many fibroblasts travel to the site of an injury, large amounts of collagen can be deposited, producing excessive, fibrotic scarring. Fibroblasts are known to be pre
'/>"/>
| Contact: Sue McGreevey smcgreevey@partners.org 617-724-2764 Massachusetts General Hospital Source:Eurekalert |
Related medicine news :
1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
(Date:12/2/2009)...ment seen for advanced cases, study finds , ... past two decades, survival rates for advanced lun...ed modestly, a new study has found. , Researche...gnosed with stage 4 non-small cell lung cancer (NS...n was in the U.S. National Cancer Institute,s Surv...
(Date:12/2/2009)...sing incidence of obesity could counter recent inc...2 (HealthDay News) -- The overall health of the U....ades, largely because people have quit smoking in ... soon be wiped out if the rising obesity rates amo...ent trends in both smoking and obesity continue un...
(Date:12/2/2009)...ally likely to have metabolic syndrome, study find... -- Exercise alone isn,t enough to keep overweight...k for a medical condition that can lead to heart d...died linemen at Division I colleges and found that...etabolic syndrome, a group of conditions that rais...
(Date:12/2/2009)...es now available, many more to come, NIH director ...News) -- Thirteen stem cell lines have been added...funded research, and many more such lines will soo...ed Wednesday. , These are the first additional ...nded by the U.S. National Institutes of Health (NI...
(Date:12/2/2009)...IRGINIA BEACH, Va., Dec. 2 By now,...smokeless cigarettes continue to grow in popularit...ailable at the PremiumEcigarette - the new single ...te - at the amazingly low price of $14.99. ,, "...ry the e-cigarette at a very low price, before mak...
Breaking Medicine News(10 mins):Health News:Gains Made in Lung Cancer Survival 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:Oversized College Football Players May Face Heart Risks 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2[0] Gains Made in Lung Cancer Survival[0] Health Gains From Lowered Smoking Rates in Jeopardy[0] Oversized College Football Players May Face Heart Risks[0] U.S. Approves New Stem Cell Lines for Publicly Funded Research[2] A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product
...ana, and the Netherlands boost,disability field,s ...eting,with assessment results, WASHINGTON, July 1...rvices is how to allocate limited resources and fu...ent tool, developed by the American Association on...
...pproximately 200,000,women across the U.S. undergo...r ovaries are removed during a hysterectomy. While...they prepared for what comes next?, Listen to thi...graphics and,photos for free and unrestricted use ...
...immune, Inc., a privately,held biotechnology compa...,of $8.9 million of its Series D preferred stock o...erprise Associates, MPM Capital, Hunt Ventures,L.P...advance clinical development of Peptimmune,s PI-23...
...008 Anxiety is a normal human response to stress,...rder of excessive and irrational fears, such as ob...sttraumatic stress disorder. Effective treatments... result in even better results," David Tolin, Ph.D...
...evier, a leading publisher of scientific, technica...an Urology , the official journal of the European...d impact factor of 5.634. , European Urology ...idly evolving world of medicine, technology and su...
... cross contaminations including Norovirus ...a., July 16 Seal Shield LLC has begun,shipping a ...ional,keyboards with SILVER SEAL Antimicrobial pro...SEAL(TM) International Keyboard,is the world,s fir...
Other Medicine News:Health News:The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals 2Health News:Peptimmune Announces the Second Close of Series D Private Financing 2Health News:D-cycloserine may improve behavioral therapy treatment for anxiety 2Health News:Seal Shield to Launch World's First Dishwasher Safe, Antimicrobial Keyboard with Multi-Language Support for International Markets 2The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research RevealsAUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical MenopausePeptimmune Announces the Second Close of Series D Private FinancingD-cycloserine may improve behavioral therapy treatment for anxiety5.634 -- the new impact factor of European Urology underlines the journal's outstanding positionSeal Shield to Launch World's First Dishwasher Safe, Antimicrobial Keyboard with Multi-Language Support for International Markets
(Date:12/2/2009)..., Sweden, December 2 DermaGen AB -...d wound healing company "Pergamum" -,today announc... from a,clinical Phase I/IIa study. DermaGen AB is...eatment for atopic dermatitis. Atopic dermatitis i...in and the skin,s weakened barrier,function make p...
(Date:12/2/2009).... 2 Novavax, Inc. (Nasda...s from the first stage of a two-stage pivotal Phas...y of the company,s 2009 H1N1 virus-like particle (...cting this study in collaboration with Avimex Labo...vaccine in Mexico and potentially other countries....
(Date:12/2/2009)... Keryx Biopharmaceutical...U.S. Food and Drug Administration (FDA) has grante..., the Company,s novel, potentially first-in-class,...nositide 3-kinase (PI3K)/Akt pathway, for the trea..., The Fast Track program of the FDA is designed...
Breaking Medicine Technology:Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Phylicia Rashad Reaches Weight Loss Goal 3B Loses 35 lbs 54698 1Phylicia Rashad Reaches Weight Loss Goal 3B Loses 35 lbs 54698 2U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 1U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 2U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 3U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 4Attendance on Demand Inc Hosts Free Webinar Top 5 Tools to Control Labor Costs for Long Term Healthcare Professionals 2 3A30pm EDT August 26 2009 54692 1Attendance on Demand Inc Hosts Free Webinar Top 5 Tools to Control Labor Costs for Long Term Healthcare Professionals 2 3A30pm EDT August 26 2009 54692 2[0] Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis[0] NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico[0] Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
...(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CY...mpleted an important,pilot study with a novel synD...nd intended to protect against the avian (H5N1),in...bust protective,effect in mice treated with the Co...ed control animals died after both groups,were cha...
...TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 ... following a,planned meeting of the independent Da...SSERT trial of senicapoc (formerly,ICA-17043) for ...e,DMC recommended that the trial be terminated bec...on in crisis rate, the primary,endpoint. In making...
Other Medicine Technology:CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |